Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00343876|
Recruitment Status : Completed
First Posted : June 23, 2006
Last Update Posted : August 21, 2008
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Drug: aspirin Drug: clopidogrel||Phase 4|
The objective of this trial is to assess the effects of combined therapy of clopidogrel and aspirin versus placebo and aspirin on CRP in patients with known CAD.
Potential subjects already on stable aspirin and statin therapy will be randomized to clopidogrel vs. placebo in a I: 1 design. Participants will undergo study therapy for 3 months. Various laboratory parameters, including serum plasma concentration of CRP, will be assessed throughout the study. The primary endpoint is the effect of study therapy on CRP.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Single Center, Double-Blind, Randomized Trial to Evaluate the Effects of Aspirin 325 mg + Clopidogrel 75 mg v. Aspirin 325 mg + Placebo on Plasma Concentration of C-Reactive Protein: The CATER Trial Protocol|
|Study Start Date :||July 2005|
|Actual Study Completion Date :||November 2006|
- The primary endpoint is the observation of the effect of aspirin + clopidogrel vs.
- aspirin + placebo on CRP levels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00343876
|United States, Utah|
|Salt Lake City, Utah, United States, 84143|
|Principal Investigator:||Joseph B Muhlestein, MD||Intermountain Healthcare, LDS Hospital|